Collegium Pharmaceutical (NASDAQ:COLL) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a report released on Saturday.

COLL has been the topic of a number of other research reports. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Trading Down 1.1%

Shares of COLL stock opened at $35.20 on Friday. The company’s fifty day simple moving average is $34.65 and its two-hundred day simple moving average is $37.94. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical has a 1 year low of $29.19 and a 1 year high of $50.79. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 17.25 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.49 earnings per share. As a group, analysts anticipate that Collegium Pharmaceutical will post 6.76 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in COLL. Wedge Capital Management L L P NC bought a new position in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $2,697,000. Vanguard Group Inc. lifted its position in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Collegium Pharmaceutical by 193.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 211,757 shares of the specialty pharmaceutical company’s stock worth $7,409,000 after buying an additional 139,689 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after buying an additional 518,721 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in shares of Collegium Pharmaceutical in the 1st quarter worth $463,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.